{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:10:34Z","timestamp":1795133434240,"version":"4.10.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["016.126.612"],"award-info":[{"award-number":["016.126.612"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["grant 132"],"award-info":[{"award-number":["grant 132"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["grant 264"],"award-info":[{"award-number":["grant 264"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["AMC 2008-4265"],"award-info":[{"award-number":["AMC 2008-4265"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["EMCR 2014-6998"],"award-info":[{"award-number":["EMCR 2014-6998"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high frequency of copy number alterations (CNAs) in\n                    <jats:italic>IKZF1<\/jats:italic>\n                    ,\n                    <jats:italic>EBF1<\/jats:italic>\n                    ,\n                    <jats:italic>PAX5<\/jats:italic>\n                    ,\n                    <jats:italic>CDKN2A\/B<\/jats:italic>\n                    ,\n                    <jats:italic>RB1<\/jats:italic>\n                    ,\n                    <jats:italic>BTG1<\/jats:italic>\n                    ,\n                    <jats:italic>ETV6<\/jats:italic>\n                    , and\/or the PAR1 region (henceforth: B-cell development genes). We aimed to gain insight in the association between CNAs in these genes, clinical outcome parameters, and cellular drug resistance. 71% of newly diagnosed pediatric BCP-ALL cases harbored one or more CNAs in these B-cell development genes. The distribution and clinical relevance of these CNAs was highly subtype-dependent. In the DCOG-ALL10 cohort, only loss of\n                    <jats:italic>IKZF1<\/jats:italic>\n                    associated as single marker with unfavorable outcome parameters and cellular drug resistance. Prednisolone resistance was observed in\n                    <jats:italic>IKZF1<\/jats:italic>\n                    -deleted primary high hyperdiploid cells (~1500-fold), while thiopurine resistance was detected in\n                    <jats:italic>IKZF1<\/jats:italic>\n                    -deleted primary\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    -like and non-\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    -like B-other cells (~2.7-fold). The previously described risk stratification classifiers, i.e.\n                    <jats:italic>IKZF1<\/jats:italic>\n                    <jats:sup>plus<\/jats:sup>\n                    and integrated cytogenetic and CNA classification, both predicted unfavorable outcome in the DCOG-ALL10 cohort, and associated with\n                    <jats:italic>ex vivo<\/jats:italic>\n                    drug cellular resistance to thiopurines, or L-asparaginase and thiopurines, respectively. This resistance could be attributed to overrepresentation of\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    -like cases in these risk groups. Taken together, our data indicate that the prognostic value of CNAs in B-cell development genes is linked to subtype-related drug responses.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-41078-4","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T07:02:32Z","timestamp":1552633352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"9","author":[{"given":"Elisabeth M. P.","family":"Steeghs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Q.","family":"Hoogkamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"de Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester A.","family":"de Groot-Kruseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"41078_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","volume":"26","author":"AV Moorman","year":"2012","unstructured":"Moorman, A. V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood reviews 26, 123\u2013135, https:\/\/doi.org\/10.1016\/j.blre.2012.01.001 (2012).","journal-title":"Blood reviews"},{"key":"41078_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030\u20131043, https:\/\/doi.org\/10.1016\/S0140-6736(08)60457-2 (2008).","journal-title":"Lancet"},{"key":"41078_CR3","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters, R. et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 34, 2591\u20132601, https:\/\/doi.org\/10.1200\/JCO.2015.64.6364 (2016).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"41078_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 10, 125\u2013134, https:\/\/doi.org\/10.1016\/S1470-2045(08)70339-5 (2009).","journal-title":"Lancet Oncol"},{"key":"41078_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England journal of medicine 360, 470\u2013480, https:\/\/doi.org\/10.1056\/NEJMoa0808253 (2009).","journal-title":"The New England journal of medicine"},{"key":"41078_CR6","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.18632\/oncotarget.13492","volume":"8","author":"JM Boer","year":"2017","unstructured":"Boer, J. M. et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget 8, 4618\u20134628, https:\/\/doi.org\/10.18632\/oncotarget.13492 (2017).","journal-title":"Oncotarget"},{"key":"41078_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.28","volume":"6","author":"T Imamura","year":"2016","unstructured":"Imamura, T. et al. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood cancer journal 6, e419, https:\/\/doi.org\/10.1038\/bcj.2016.28 (2016).","journal-title":"Blood cancer journal"},{"key":"41078_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. The New England journal of medicine 371, 1005\u20131015, https:\/\/doi.org\/10.1056\/NEJMoa1403088 (2014).","journal-title":"The New England journal of medicine"},{"key":"41078_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22, 153\u2013166, https:\/\/doi.org\/10.1016\/j.ccr.2012.06.005 (2012).","journal-title":"Cancer Cell"},{"key":"41078_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11790","volume":"7","author":"H Lilljebjorn","year":"2016","unstructured":"Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nature communications 7, 11790, https:\/\/doi.org\/10.1038\/ncomms11790 (2016).","journal-title":"Nature communications"},{"key":"41078_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nature genetics 48, 569\u2013574, https:\/\/doi.org\/10.1038\/ng.3535 (2016).","journal-title":"Nature genetics"},{"key":"41078_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature genetics 48, 1481\u20131489, https:\/\/doi.org\/10.1038\/ng.3691 (2016).","journal-title":"Nature genetics"},{"key":"41078_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3324\/haematol.2015.141101","volume":"101","author":"AV Moorman","year":"2016","unstructured":"Moorman, A. V. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 101, 407\u2013416, https:\/\/doi.org\/10.3324\/haematol.2015.141101 (2016).","journal-title":"Haematologica"},{"key":"41078_CR14","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer, A. et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122, 2622\u20132629, https:\/\/doi.org\/10.1182\/blood-2012-10-462358 (2013).","journal-title":"Blood"},{"key":"41078_CR15","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","volume":"116","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874\u20134884, https:\/\/doi.org\/10.1182\/blood-2009-08-239681 (2010).","journal-title":"Blood"},{"key":"41078_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2015.199","volume":"30","author":"JM Boer","year":"2016","unstructured":"Boer, J. M. et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 30, 32\u201338, https:\/\/doi.org\/10.1038\/leu.2015.199 (2016).","journal-title":"Leukemia"},{"key":"41078_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/leu.2010.87","volume":"24","author":"RP Kuiper","year":"2010","unstructured":"Kuiper, R. P. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 24, 1258\u20131264, https:\/\/doi.org\/10.1038\/leu.2010.87 (2010).","journal-title":"Leukemia"},{"key":"41078_CR18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1182\/blood-2014-03-562918","volume":"124","author":"AV Moorman","year":"2014","unstructured":"Moorman, A. V. et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 124, 1434\u20131444, https:\/\/doi.org\/10.1182\/blood-2014-03-562918 (2014).","journal-title":"Blood"},{"key":"41078_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10428194.2016.1193855","volume":"58","author":"SK Gupta","year":"2017","unstructured":"Gupta, S. K., Bakhshi, S., Kumar, L., Kamal, V. K. & Kumar, R. Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia. Leukemia & lymphoma 58, 333\u2013342, https:\/\/doi.org\/10.1080\/10428194.2016.1193855 (2017).","journal-title":"Leukemia & lymphoma"},{"key":"41078_CR20","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla, M. et al. IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 36, 1240\u20131249, https:\/\/doi.org\/10.1200\/JCO.2017.74.3617 (2018).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"41078_CR21","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","volume":"21","author":"ML Den Boer","year":"2003","unstructured":"Den Boer, M. L. et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21, 3262\u20133268, https:\/\/doi.org\/10.1200\/JCO.2003.11.031 (2003).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"41078_CR22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V92.1.259.413k21_259_266","volume":"92","author":"GJ Kaspers","year":"1998","unstructured":"Kaspers, G. J. et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 92, 259\u2013266 (1998).","journal-title":"Blood"},{"key":"41078_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0140-6736(91)91029-T","volume":"338","author":"R Pieters","year":"1991","unstructured":"Pieters, R. et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338, 399\u2013403 (1991).","journal-title":"Lancet"},{"key":"41078_CR24","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","volume":"86","author":"E Klumper","year":"1995","unstructured":"Klumper, E. et al. In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia. Blood 86, 3861\u20133868 (1995).","journal-title":"Blood"},{"key":"41078_CR25","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/leu.2015.359","volume":"30","author":"R Marke","year":"2016","unstructured":"Marke, R. et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 30, 1599\u20131603, https:\/\/doi.org\/10.1038\/leu.2015.359 (2016).","journal-title":"Leukemia"},{"key":"41078_CR26","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/leu.2016.128","volume":"30","author":"T Imamura","year":"2016","unstructured":"Imamura, T. et al. IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance. Leukemia 30, 1801\u20131803, https:\/\/doi.org\/10.1038\/leu.2016.128 (2016).","journal-title":"Leukemia"},{"key":"41078_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2016.153023","volume":"102","author":"B Scheijen","year":"2017","unstructured":"Scheijen, B. et al. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Haematologica 102, 541\u2013551, https:\/\/doi.org\/10.3324\/haematol.2016.153023 (2017).","journal-title":"Haematologica"},{"key":"41078_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3324\/haematol.2013.085175","volume":"98","author":"CJ Schwab","year":"2013","unstructured":"Schwab, C. J. et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica 98, 1081\u20131088, https:\/\/doi.org\/10.3324\/haematol.2013.085175 (2013).","journal-title":"Haematologica"},{"key":"41078_CR29","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","volume":"114","author":"LJ Russell","year":"2009","unstructured":"Russell, L. J. et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114, 2688\u20132698, https:\/\/doi.org\/10.1182\/blood-2009-03-208397 (2009).","journal-title":"Blood"},{"key":"41078_CR30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2010.63","volume":"24","author":"C Virely","year":"2010","unstructured":"Virely, C. et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 24, 1200\u20131204, https:\/\/doi.org\/10.1038\/leu.2010.63 (2010).","journal-title":"Leukemia"},{"key":"41078_CR31","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","volume":"123","author":"A van der Veer","year":"2014","unstructured":"van der Veer, A. et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123, 1691\u20131698, https:\/\/doi.org\/10.1182\/blood-2013-06-509794 (2014).","journal-title":"Blood"},{"key":"41078_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/leu.2013.277","volume":"28","author":"E Clappier","year":"2014","unstructured":"Clappier, E. et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28, 70\u201377, https:\/\/doi.org\/10.1038\/leu.2013.277 (2014).","journal-title":"Leukemia"},{"key":"41078_CR33","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/leu.2013.136","volume":"27","author":"A Enshaei","year":"2013","unstructured":"Enshaei, A. et al. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia 27, 2256\u20132259, https:\/\/doi.org\/10.1038\/leu.2013.136 (2013).","journal-title":"Leukemia"},{"key":"41078_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature21076","volume":"542","author":"LN Chan","year":"2017","unstructured":"Chan, L. N. et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 542, 479\u2013483, https:\/\/doi.org\/10.1038\/nature21076 (2017).","journal-title":"Nature"},{"key":"41078_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa033513","volume":"351","author":"A Holleman","year":"2004","unstructured":"Holleman, A. et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. The New England journal of medicine 351, 533\u2013542, https:\/\/doi.org\/10.1056\/NEJMoa033513 (2004).","journal-title":"The New England journal of medicine"},{"key":"41078_CR36","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/blood-2008-05-157842","volume":"113","author":"E Hulleman","year":"2009","unstructured":"Hulleman, E. et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113, 2014\u20132021, https:\/\/doi.org\/10.1182\/blood-2008-05-157842 (2009).","journal-title":"Blood"},{"key":"41078_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0150-6","volume":"7","author":"L Chouchana","year":"2015","unstructured":"Chouchana, L. et al. Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines. Genome medicine 7, 37, https:\/\/doi.org\/10.1186\/s13073-015-0150-6 (2015).","journal-title":"Genome medicine"},{"key":"41078_CR38","doi-asserted-by":"publisher","first-page":"e40934","DOI":"10.1371\/journal.pone.0040934","volume":"7","author":"I Iacobucci","year":"2012","unstructured":"Iacobucci, I. et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PloS one 7, e40934, https:\/\/doi.org\/10.1371\/journal.pone.0040934 (2012).","journal-title":"PloS one"},{"key":"41078_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/leu.2013.317","volume":"28","author":"CJ Harrison","year":"2014","unstructured":"Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015\u20131021, https:\/\/doi.org\/10.1038\/leu.2013.317 (2014).","journal-title":"Leukemia"},{"key":"41078_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature genetics 45, 242\u2013252, https:\/\/doi.org\/10.1038\/ng.2532 (2013).","journal-title":"Nature genetics"},{"key":"41078_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","volume":"10","author":"AJ Veerman","year":"2009","unstructured":"Veerman, A. J. et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997\u20132004). Lancet Oncol 10, 957\u2013966, https:\/\/doi.org\/10.1016\/S1470-2045(09)70228-1 (2009).","journal-title":"Lancet Oncol"},{"key":"41078_CR42","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2010.039735","volume":"96","author":"G Escherich","year":"2011","unstructured":"Escherich, G. et al. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 96, 854\u2013862, https:\/\/doi.org\/10.3324\/haematol.2010.039735 (2011).","journal-title":"Haematologica"},{"key":"41078_CR43","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/sj.leu.2404535","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden, V. H. et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21, 706\u2013713, https:\/\/doi.org\/10.1038\/sj.leu.2404535 (2007).","journal-title":"Leukemia"},{"key":"41078_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","volume":"538","author":"VH van der Velden","year":"2009","unstructured":"van der Velden, V. H. & van Dongen, J. J. MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR. Methods in molecular biology 538, 115\u2013150, https:\/\/doi.org\/10.1007\/978-1-59745-418-6_7 (2009).","journal-title":"Methods in molecular biology"},{"key":"41078_CR45","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1038\/leu.2009.135","volume":"23","author":"J Familiades","year":"2009","unstructured":"Familiades, J. et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 23, 1989\u20131998, https:\/\/doi.org\/10.1038\/leu.2009.135 (2009).","journal-title":"Leukemia"},{"key":"41078_CR46","unstructured":"Gray, R. J. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-6. http:\/\/CRAN.R-project.org\/package=cmprsk (2013)."},{"key":"41078_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","volume":"38","author":"LC De Wreede","year":"2011","unstructured":"De Wreede, L. C., Fiocco, M. & Putter, H. mstate: An R Package for the Analysis of Competing Risks and Multi-State Models. J Stat Softw 38, 1\u201330 (2011).","journal-title":"J Stat Softw"},{"key":"41078_CR48","unstructured":"Therneau, T. A Package for Survival Analysis in S. R package version 2.36-12 (2012)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41078-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:41:40Z","timestamp":1671244900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41078"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41078-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4634"}}